Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl
Melanie P Chin, Scott A Reisman, George L Bakris, Megan O'Grady, Peter G Linde, Peter A McCullough, David Packham, Nosratola D Vaziri, Keith W Ward, David G Warnock, Colin J Meyer
American Journal of Nephrology | KARGER | Published : 2014
G.L.B., P.A.M., D.P., and N.D.V. have received honoraria from Reata Pharmaceuticals for their involvement with the BEACON trial. D.G.W. is a consultant to, and has an equity interest in Reata. M.P.C., S.A.R., M.O.G., K.W.W., and C.J.M. are employed by and/or have a financial interest in Reata. P.G.L. is employed by Abb Vie.